Prascend 1 mg Tablets for Horses
देश: यूनाइटेड किंगडम
भाषा: अंग्रेज़ी
स्रोत: VMD (Veterinary Medicines Directorate)
उत्पाद विशेषताएं
(SPC)
27-10-2015
इस उत्पाद के लिए कुछ दस्तावेज़ वर्तमान में उपलब्ध नहीं हैं, आप हमारी ग्राहक सेवा को अनुरोध भेज सकते हैं और जैसे ही हम उन्हें प्राप्त करने में सक्षम होंगे, हम आपको सूचित करेंगे।
अनुरोध भेजा।
अनुरोध भेजा।
सक्रिय संघटक:
Pergolide
थमां उपलब्ध:
Boehringer Ingelheim Ltd
ए.टी.सी कोड:
QN04BC02
INN (इंटरनेशनल नाम):
Pergolide
फार्मास्यूटिकल फॉर्म:
Tablet
प्रिस्क्रिप्शन प्रकार:
POM-V - Prescription Only Medicine – Veterinarian
चिकित्सीय समूह:
Horses
चिकित्सीय क्षेत्र:
Neurological Agent
प्राधिकरण का दर्जा:
Authorized
प्राधिकरण की तारीख:
2010-03-11
उत्पाद विशेषताएं
Revised: October 2015
AN: 00495/2015
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Prascend 1 mg tablets for horses
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCE:
1.0 mg pergolide (as pergolide mesylate 1.31 mg)
EXCIPIENTS:
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Pink, rectangular scored tablet, engraved on one side with the Boehringer Ingelheim
logo and the letters “PRD”. The tablets can be divided into equal halves.
4.
CLINICAL PARTICULARS
4.1 TARGET SPECIES
Horses not intended for human consumption
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Symptomatic treatment of clinical signs associated with Pituitary Pars Intermedia
Dysfunction (PPID) (Equine Cushing’s Disease).
4.3 CONTRAINDICATIONS
Do not use in horses with known hypersensitivity to pergolide mesylate or other ergot
derivatives or to any of the excipients.
Do not use in horses less than 2 years of age.
4.4 SPECIAL WARNINGS
Appropriate endocrinologic laboratory tests should be conducted as well as evaluation
of clinical signs in order to establish a diagnosis of PPID.
4.5 SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
As the majority of cases of PPID are diagnosed in aged horses, other pathological
processes are frequently present. For monitoring and frequency of testing, see section
4.9.
Special precautions to be taken by the person administering the medicinal product to
animals
Page 1 of 6
Revised: October 2015
AN: 00495/2015
This product may cause eye irritation, an irritating smell, or headache after splitting.
Minimise exposure risks when splitting tablets. Tablets should not be crushed.
Avoid contact with the eyes and inhalation when handling the tablets.
Wash
पूरा दस्तावेज़ पढ़ें
